Sysmex (SSMXY) Projected to Post Quarterly Earnings on Wednesday

Sysmex (OTCMKTS:SSMXY) is anticipated to post its resultson Wednesday, August 5th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $739.4560 million for the quarter. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The business had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. On average, analysts expect Sysmex to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sysmex Trading Up 2.1%

Shares of OTCMKTS SSMXY traded up $0.20 during midday trading on Wednesday, hitting $10.15. The company’s stock had a trading volume of 554 shares, compared to its average volume of 224,973. Sysmex has a 12-month low of $8.01 and a 12-month high of $16.90. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The firm has a market cap of $6.39 billion, a P/E ratio of 26.72 and a beta of 1.07. The business’s 50 day moving average is $9.13 and its two-hundred day moving average is $9.05.

Analysts Set New Price Targets

Separately, Zacks Research downgraded Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Sysmex has a consensus rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.